HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation

Table 1

Transplanted patient demographics.

	HCV (N=44)	Non HCV (N=84)	P Value
Age, mean±SD [range]	59.6±5.0	49.3± 13.9	P<0.001
Gender, N=Male ( Male)	35 (79.6)	55 (65.5)	P=0.099
BMI at Transplant, mean±SD [range]	27.9±4.9	27.3±6.1	P=0.552
MELD-Na at Activation, mean±SD [range]	16.9±7.4	22.1±8.2	P=0.001
Waitlist MELD for Activation, mean±SD [range]	21.4±6.0	23.5±7.0	P=0.109
MELD-Na at Transplant, mean±SD [range]	20.4±8.3	24.4±9.2	P=0.018
Waitlist MELD at Transplant, mean±SD [range]	26.4± 6.3	27.3±7.4	P=0.534
Days on waitlist prior to transplant, mean±SD [range]	410.6±504.6	225.9±28.8	P=0.007
HCV SVR Pre-Transplant (N=17)	492.0±619.1
			P=0.308
Untreated Pre-Transplant (N=27)	415.0±407.7
	HCV Genotype, N ()
1	34 (77.3)
2	2 (4.5)
3	7 (15.9)
4	1 (2.3)
Diagnosis, N ()
HCV Alone	14 (31.8)
HCV & HCC	30 (68.2)
HCC, underlying diagnosis [N]		16 (19.0)
ETOH
HBV
NASH
PBC
PSC
Chronic cholestatic (PBC, PSC)		23 (27.4)
Hepatocellular (Cryptogenic, AIH, HBV, NASH, ETOH)		31 (36.9)
Metabolic (A1AT, Urea Cycle)		4 (4.8)
Acute Failure (Seronegative Hepatitis, Tylenol Overdose)		5 (6.0)
Other		5 (6.0)